(Q34829905)

4 August 2017

title

Access to orphan drugs despite poor quality of clinical evidence (English)

1 reference

4 August 2017

1 reference

Alain G Dupont

1

1 reference

4 August 2017

Philippe B Van Wilder

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

British Journal of Clinical Pharmacology

4 August 2017

published in

1 reference

4 August 2017

volume

71

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

488-496

1 reference

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

Why rare diseases are an important medical and social issue

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

A journey of hope: lessons learned from studies on rare diseases and orphan drugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

Orphan drug development is progressing too slowly

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

Orphan drugs and the NHS: should we value rarity?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

Drugs for exceptionally rare diseases: do they deserve special status for funding?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

Two decades of orphan product development

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3080635

Does orphan drug legislation really answer the needs of patients?

8 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2010.03877.X

Orphan drug development is not taking off.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2010.03877.X

Clinical trials of orphan medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2010.03877.X

21 January 2018

Orphan drugs revisited.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2010.03877.X

Rationing of Drugs for Rare Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2010.03877.X

Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome?

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Assessing the economic challenges posed by orphan drugs

1 reference

12 December 2020

Quantifying emerging drugs for very rare conditions

1 reference

12 December 2020

Reimbursement of medicines in Belgium: role of evidence-based medicine

1 reference

12 December 2020

10.1111/J.1365-2125.2010.03877.X

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference